Eagle Pharmaceuticals Inc (NASDAQ:EGRX) has been given a consensus rating of “Hold” by the six research firms that are currently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and three have assigned a buy recommendation to the company. The average 1 year target price among brokers that have covered the stock in the last year is $63.67.

EGRX has been the topic of a number of research reports. Royal Bank of Canada reaffirmed an “outperform” rating and set a $75.00 price target (down from $81.00) on shares of Eagle Pharmaceuticals in a research note on Thursday, November 9th. Mizuho reaffirmed a “sell” rating and set a $37.00 price target on shares of Eagle Pharmaceuticals in a research note on Wednesday, November 8th. Piper Jaffray Companies reaffirmed a “buy” rating and set a $75.00 price target on shares of Eagle Pharmaceuticals in a research note on Friday, October 27th. Zacks Investment Research downgraded Eagle Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, January 9th. Finally, BidaskClub lowered Eagle Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, January 18th.

Eagle Pharmaceuticals (EGRX) traded up $2.58 during mid-day trading on Friday, reaching $59.39. The company had a trading volume of 184,700 shares, compared to its average volume of 205,726. Eagle Pharmaceuticals has a fifty-two week low of $45.05 and a fifty-two week high of $97.15. The company has a current ratio of 5.30, a quick ratio of 5.15 and a debt-to-equity ratio of 0.26. The firm has a market cap of $847.70, a P/E ratio of 9.58 and a beta of 1.25.

Institutional investors and hedge funds have recently modified their holdings of the business. Advisory Services Network LLC increased its holdings in Eagle Pharmaceuticals by 52.8% during the 2nd quarter. Advisory Services Network LLC now owns 12,225 shares of the specialty pharmaceutical company’s stock worth $964,000 after purchasing an additional 4,225 shares in the last quarter. Schwab Charles Investment Management Inc. increased its holdings in Eagle Pharmaceuticals by 63.9% during the 3rd quarter. Schwab Charles Investment Management Inc. now owns 60,716 shares of the specialty pharmaceutical company’s stock worth $3,622,000 after purchasing an additional 23,663 shares in the last quarter. Ameriprise Financial Inc. increased its holdings in Eagle Pharmaceuticals by 4.2% during the 3rd quarter. Ameriprise Financial Inc. now owns 138,619 shares of the specialty pharmaceutical company’s stock worth $8,267,000 after purchasing an additional 5,548 shares in the last quarter. U S Global Investors Inc. bought a new stake in Eagle Pharmaceuticals during the 2nd quarter worth approximately $1,097,000. Finally, Vanguard Group Inc. increased its holdings in Eagle Pharmaceuticals by 22.7% during the 2nd quarter. Vanguard Group Inc. now owns 561,820 shares of the specialty pharmaceutical company’s stock worth $44,322,000 after purchasing an additional 103,760 shares in the last quarter.

TRADEMARK VIOLATION NOTICE: This piece of content was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of United States and international copyright law. The correct version of this piece of content can be read at https://www.thecerbatgem.com/2018/02/13/brokerages-set-eagle-pharmaceuticals-inc-egrx-price-target-at-63-67.html.

About Eagle Pharmaceuticals

Eagle Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses on developing and commercializing injectable products in the critical care and oncology areas. The Company’s product portfolio includes products, including Argatroban; Ryanodex; docetaxel injection, non-alcohol formulation; and Bendeka.

Receive News & Ratings for Eagle Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.